CompoAtlas

PremierZen Extreme 3000

Finding published by the FDA

Finding published by the FDA

Finding date: 17 December 2020.

Undeclared tadalafil

FDA finding date
17 December 2020
Company
name not reproduced (no recognised company form)
Subject published by the FDA
Undeclared tadalafil
Published action
Public Notification
Programme
Drugs
Published follow-up
News ReleaseRecall (QMART)Recall (Yolo Studio)Untitled Letter

This official finding is dated and does not necessarily describe the product currently sold under this name. It does not constitute an analysis of its complete composition.

The subject and action are reproduced as published by the FDA, without generalisation to all batches or other products from the company.

Substances named in the FDA finding

Published namePublished text and quantityRecognised ingredientRole or context
tadalafilUndeclared tadalafilNot recognisedSubstance named by the FDA

Substances named in the FDA finding do not constitute a complete composition. No quantity or dose is inferred.

Sites cited by the FDA

amazon.com

Official source

View the FDA finding

Related FDA document

Related FDA document

Related FDA document

Food and Drug Administration, Health Fraud Product Database. Dated official findings.

Domaine public (politique du site FDA)

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “PremierZen Extreme 3000”, https://compoatlas.com/en/supplements/us-fraud/c1e2a79239a1908e9399ed20643d5355c8dea178abc94867e690900a0a2b391f-premierzen-extreme-3000, updated 28 October 2026.

Enter to analyse, Shift+Enter for a new line